Vitality Watch

Dossier pubmed review 30-jul-2026
Narrative review or expert overview without new data

Advances in anti-aging Drug research leveraging multi-omics and artificial intelligence.

Key claim: Deep integration of multi-omics and artificial intelligence can accelerate precision anti-aging drug development via better biomarker screening, target prediction, virtual screening, and clinical-trial design.

Abstract

The intensifying global population aging has rendered the development of anti-aging drugs a core challenge in the life sciences domain. Traditional models struggle to address the systemic and networked nature of aging. Multi-omics technologies provide a panoramic perspective for deciphering molecular networks of aging, while Artificial Intelligence (AI) has demonstrated significant advantages in target discovery, drug screening, and clinical trial optimization. This review systematically elaborates on the pathological characteristics and molecular mechanisms of aging, analyzes the application paradigms of multi-omics in biomarker screening, mechanism elucidation, and high-throughput screening, and discusses the core value and technical bottlenecks of AI in target prediction, virtual screening, and trial design. Simultaneously, this paper addresses critical challenges including ethical controversies and data standardization currently confronting the field, and explores the prospects of precision anti-aging drug development and personalized treatment strategies driven by deep integration of multi-omics and AI. This approach offers novel theoretical frameworks and practical pathways for extending human healthspan.

Why this matters

Deep integration of multi-omics and artificial intelligence can accelerate precision anti-aging drug development via better biomarker screening, target prediction, virtual screening, and clinical-trial design.

Source

Link

Briefing card

Advances in anti-aging Drug research leveraging multi-omics and artificial intelligence.
Stage: review · pubmed · 30-jul-2026

Deep integration of multi-omics and artificial intelligence can accelerate precision anti-aging drug development via better biomarker screening, target prediction, virtual screening, and clinical-trial design.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.3389/fragi.2026.1868486

build build 880 · 2bcef25 · 2026-11-18